Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 16, 2022 06:30 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Announces Agreement with LifeSci Special Opportunities

LifeSci Special Opportunities Master Fund Announces Support for Diffusion’s Ongoing, Board-led Strategic Review Process and for Diffusion’s Nominees at 2022 Annual Meeting New Director to be...
November 14, 2022 06:30 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Sees Significant Progress in its Strategic Review Process

Diffusion in Active Bidding Stage and Encouraged by Response to the Strategic Review Process Diffusion Board of Directors Rejects Woefully Inadequate, Unsolicited Offer for the Company by client of...
October 25, 2022 06:30 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Announces Strategic Review Process to Evaluate Value-Enhancing Alternatives including Opportunities to Better Leverage TSC

CHARLOTTESVILLE, Va., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...
July 26, 2022 07:30 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals to Initiate Phase 2 Trial in Patients with Glioblastoma Multiforme Incorporating Innovative Imaging Methodology to Evaluate Tumor Oxygenation

Diffusion aligns with FDA on design of an open-label, dose-escalation, Phase 2 safety and efficacy study of trans sodium crocetinate (“TSC”) in newly diagnosed glioblastoma multiforme (“GBM”)...
June 23, 2022 07:30 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Announces Positive Effects in Altitude Trial

Positive effects on oxygenation observed with the 2.5 mg/kg dose at the end of the exercise intervalPositive effects on post-exercise recovery based when comparing measurements 10 min post-exercise to...
December 01, 2021 07:02 ET | Source: Diffusion Pharmaceuticals Inc.

Diffusion Pharmaceuticals Announces Issuance of U.S. Patent 11,185,523

CHARLOTTESVILLE, Va., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that...